article thumbnail

Stakeholder Mapping for Pharmaceutical Products

Celeritas

Stakeholder Mapping involves identifying professionals in the target therapeutic field who would utilize or influence the utilization of the pharmaceutical product. Contacting stakeholders can be key to knowing where they stand upon the release of the pharmaceutical product. What is a Stakeholder Map?

article thumbnail

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. 1 Simply, pharmaceutical products are the most vulnerable to counterfeiting. 1 Simply, pharmaceutical products are the most vulnerable to counterfeiting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

TOP 10 CHALLENGES IN PHARMACEUTICAL PRODUCT LIFE CYCLE MANAGEMENT

eMediWrite

Understanding a product’s life cycle can assist a company in determining its position in the market relative to rivals and the success or failure of the product. Pharmaceutical packaging is strictly regulated and has to pay attention to ingredients, product quality, and adverse event labeling. Technology transfer.

article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. Jiangsu Hengrui Medicine overview Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products.

article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. Jiangsu Hengrui has R&D facilities in China, the US, and Japan.

article thumbnail

Camrelizumab by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Jiangsu Hengrui Medicine overview Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation. What types of medicinal products are in short supply and why?